Susquehanna International Group
SABS icon

Susquehanna International Group’s SAB Biotherapeutics SABS Stock Holding History

Susquehanna International Group’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.71M Buy
+438,515
New +$1.63M ﹤0.01% 6843
2023
Q1 		– Sell
-1,144
Closed -$6.75K – 13369
2022
Q4 		$6.75K Buy
+1,144
New +$10.5K ﹤0.01% 12004
2022
Q1 		– Sell
-1,512
Closed -$118K – 13847
2021
Q4 		$118K Buy
+1,512
New +$142K ﹤0.01% 12017

Other funds holding SABS

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Susquehanna International Group's SABS Position: Q2 2026 in Review

Susquehanna International Group opened a new position in SAB Biotherapeutics (SABS) in Q2 2026: 438,515 shares worth $1.71M. The stake represents ﹤0.01% of the portfolio and ranks #6843 among its holdings. This is a return to the name: Susquehanna International Group previously reported a position in SABS as recently as Q4 2022.

Susquehanna International Group first reported a position in SABS in Q4 2021 and has held it in 3 quarters since. 87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Susquehanna International Group held 438,515 shares of SAB Biotherapeutics worth $1.71M as of Q2 2026.
  • SAB Biotherapeutics was a new Susquehanna International Group position in Q2 2026.
  • SAB Biotherapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q2 2026, its #6843 holding.
  • Susquehanna International Group first reported a position in SAB Biotherapeutics in Q4 2021 and has held it in 3 quarters since.
  • 87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.